CCA
EVGN icon

Clearwater Capital Advisors’s Evogene EVGN Stock Holding History

Clearwater Capital Advisors’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$10K – 142
2020
Q2 		$10K Buy
+1,000
New +$10.8K ﹤0.01% 136

Other funds holding EVGN

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clearwater Capital Advisors's EVGN Position: Q3 2020 in Review

Clearwater Capital Advisors sold out of Evogene (EVGN) in Q3 2020, closing a stake of 1,000 shares — an estimated $10K sold.

Clearwater Capital Advisors first reported a position in EVGN in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 18 funds tracked by Wall St. Rank hold EVGN as of Q3 2020.

  • Clearwater Capital Advisors reported no remaining Evogene position as of Q3 2020 after selling out during the quarter.
  • Clearwater Capital Advisors sold 1,000 Evogene shares in Q3 2020, an estimated $10K.
  • Clearwater Capital Advisors first reported a position in Evogene in Q2 2020 and held it in 1 quarter.
  • Clearwater Capital Advisors's Evogene position peaked at $10K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Evogene as of Q3 2020.

Based on Clearwater Capital Advisors's 13F filing for Q3 2020, filed 16 Oct 2020.